| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An exceptional vaccination policy in exceptional circumstances
|
The Lancet Infectious Diseases,
|
|
|
21 |
2 |
p. 149
|
artikel
|
| 2 |
Appropriate selection of convalescent plasma donors for COVID-19
|
Tedder, Richard S
|
|
|
21 |
2 |
p. 168-169
|
artikel
|
| 3 |
Cefiderocol: the Trojan horse has arrived but will Troy fall?
|
Heil, Emily L
|
|
|
21 |
2 |
p. 153-155
|
artikel
|
| 4 |
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
|
Wunderink, Richard G
|
|
|
21 |
2 |
p. 213-225
|
artikel
|
| 5 |
Comparing the effect of PCV10 and PCV13 paediatric vaccination programmes
|
Theilacker, Christian
|
|
|
21 |
2 |
p. 170-171
|
artikel
|
| 6 |
Comparing the effect of PCV10 and PCV13 paediatric vaccination programmes – Authors' reply
|
Agudelo, Clara Inés
|
|
|
21 |
2 |
p. 171-172
|
artikel
|
| 7 |
Concerns and motivations about COVID-19 vaccination
|
Dodd, Rachael H
|
|
|
21 |
2 |
p. 161-163
|
artikel
|
| 8 |
Correction to Lancet Infect Dis 2021; 21: 163–64
|
|
|
|
21 |
2 |
p. e16
|
artikel
|
| 9 |
COVID-19 and essential pregnant worker policies
|
McDonald, Elizabeth S
|
|
|
21 |
2 |
p. 167-168
|
artikel
|
| 10 |
Defending against a difficult clostridioides with a vaccine
|
Khanna, Sahil
|
|
|
21 |
2 |
p. 157-158
|
artikel
|
| 11 |
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
|
Bassetti, Matteo
|
|
|
21 |
2 |
p. 226-240
|
artikel
|
| 12 |
Electronic health record data for antimicrobial prescribing
|
Haeusler, Gabrielle M
|
|
|
21 |
2 |
p. 155-157
|
artikel
|
| 13 |
Estimating the COVID-19 R number: a bargain with the devil?
|
Bauch, Chris T
|
|
|
21 |
2 |
p. 151-153
|
artikel
|
| 14 |
Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis
|
Yang, Wan
|
|
|
21 |
2 |
p. 203-212
|
artikel
|
| 15 |
Expecting the unexpected with COVID-19 vaccines
|
Bar-Zeev, Naor
|
|
|
21 |
2 |
p. 150-151
|
artikel
|
| 16 |
Group B streptococcus vaccines: one step further
|
Berner, Reinhard
|
|
|
21 |
2 |
p. 158-160
|
artikel
|
| 17 |
HIV and its effects on a family in the late 1980s
|
Bagcchi, Sanjeet
|
|
|
21 |
2 |
p. 180
|
artikel
|
| 18 |
Immunogenicity and persistence of trivalent measles, mumps, and rubella vaccines: a systematic review and meta-analysis
|
Schenk, Julie
|
|
|
21 |
2 |
p. 286-295
|
artikel
|
| 19 |
Implication of SARS-CoV-2 evolution in the sensitivity of RT-qPCR diagnostic assays
|
Osório, Nuno Sampaio
|
|
|
21 |
2 |
p. 166-167
|
artikel
|
| 20 |
Inappropriate empirical antibiotic therapy for bloodstream infections based on discordant in-vitro susceptibilities: a retrospective cohort analysis of prevalence, predictors, and mortality risk in US hospitals
|
Kadri, Sameer S
|
|
|
21 |
2 |
p. 241-251
|
artikel
|
| 21 |
Infectious disease surveillance update
|
Zwizwai, Ruth
|
|
|
21 |
2 |
p. 176
|
artikel
|
| 22 |
Is it time to reconsider measles, mumps, and rubella immunisation strategies?
|
Boccalini, Sara
|
|
|
21 |
2 |
p. 160-161
|
artikel
|
| 23 |
New guidelines for Lyme disease diagnosis
|
Mushtaq, Ammara
|
|
|
21 |
2 |
p. 173
|
artikel
|
| 24 |
New tuberculosis tests and drugs remain out of reach
|
Makoni, Munyaradzi
|
|
|
21 |
2 |
p. 174
|
artikel
|
| 25 |
Persistence of IgG response to SARS-CoV-2
|
Duysburgh, Els
|
|
|
21 |
2 |
p. 163-164
|
artikel
|
| 26 |
Rani Bang—leader in women's reproductive health
|
Kirby, Tony
|
|
|
21 |
2 |
p. 178
|
artikel
|
| 27 |
Ratio, rate, or risk?
|
Mantha, Srinivas
|
|
|
21 |
2 |
p. 165-166
|
artikel
|
| 28 |
Research brief
|
Devi, Sharmila
|
|
|
21 |
2 |
p. 177
|
artikel
|
| 29 |
RT-PCR for SARS-CoV-2: quantitative versus qualitative
|
Han, Mi Seon
|
|
|
21 |
2 |
p. 165
|
artikel
|
| 30 |
Safety and immunogenicity of a novel hexavalent group B streptococcus conjugate vaccine in healthy, non-pregnant adults: a phase 1/2, randomised, placebo-controlled, observer-blinded, dose-escalation trial
|
Absalon, Judith
|
|
|
21 |
2 |
p. 263-274
|
artikel
|
| 31 |
Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial
|
Adegnika, Ayola A
|
|
|
21 |
2 |
p. 275-285
|
artikel
|
| 32 |
Safety, immunogenicity, and efficacy of a Clostridioides difficile toxoid vaccine candidate: a phase 3 multicentre, observer-blind, randomised, controlled trial
|
de Bruyn, Guy
|
|
|
21 |
2 |
p. 252-262
|
artikel
|
| 33 |
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
|
Zhang, Yanjun
|
|
|
21 |
2 |
p. 181-192
|
artikel
|
| 34 |
Seroconversion in household members of COVID-19 outpatients
|
Cox, Rebecca J
|
|
|
21 |
2 |
p. 168
|
artikel
|
| 35 |
Subcutaneous fungal infection of the face
|
Chappity, Preetam
|
|
|
21 |
2 |
p. 296
|
artikel
|
| 36 |
The elusive elimination of river blindness
|
Burki, Talha
|
|
|
21 |
2 |
p. 175-176
|
artikel
|
| 37 |
The role of louse-transmitted diseases in historical plague pandemics
|
Barbieri, Rémi
|
|
|
21 |
2 |
p. e17-e25
|
artikel
|
| 38 |
The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries
|
Li, You
|
|
|
21 |
2 |
p. 193-202
|
artikel
|
| 39 |
The words that shaped COVID-19
|
Adalja, Amesh
|
|
|
21 |
2 |
p. 179
|
artikel
|
| 40 |
Underlying factors in paediatric invasive pneumococcal disease in Belgium
|
Izurieta, Patricia
|
|
|
21 |
2 |
p. 169-170
|
artikel
|
| 41 |
Underlying factors in paediatric invasive pneumococcal disease in Belgium – Authors' reply
|
Desmet, Stefanie
|
|
|
21 |
2 |
p. 170
|
artikel
|
| 42 |
What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2
|
Hodgson, Susanne H
|
|
|
21 |
2 |
p. e26-e35
|
artikel
|
Tijdschrift beschrijving